Abstract
The purpose of this study was to determine long-term renal platinum excretion after chemotherapy with cisplatin. We examined urinary platinum concentrations in 23 men at 150–3022 days after anticancer treatment for testicular neoplasm. Spot urine samples were analyzed by voltammetry. This new, subtle method with a detection limit of 2 pg platinum allows determination of even the natural background level. Urinary platinum concentrations in our patients ranged between 0.74 and 77.24 μg/g creatinine, depending on the total delivered dose and follow-up period. Regression analysis of the data showed two phases of long-term renal platinum excretion, one occurring at between 150 and 900 days of follow-up and the other with an onset at 900 days after cisplatin administration (r 1 2=0.82,r 2 2=0.88). Two biological half-lives of 160 and 720 days were calculated. Our results show that urinary platinum concentrations determined at 8 years after cisplatin therapy are 40 times higher than the background level (up to 0.02 μg/g creatinine). Our findings on the long-term pharmacolinetics of this anticancer agent may facilitate further studies on sites of platinum storage in the human body as well as clinical studies on the late adverse effects of cisplatin.
Article PDF
Avoid common mistakes on your manuscript.
References
Donohue JP (1977)cis-Diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293
Bosl G (1991/1992) Germ cell tumors. In: Wittes RE (ed) Manual of oncologic therapeutics. Lippincott, Philadelphia, p 189
Hölzel D, Altwein JE (1988) Hodentumoren — Ist der Rückgang der Mortalität in der Bundersrepublik Deutschland zu langsam erfolgt? Dtsch Ärzteblatt B 88: 2694–2700
Krakoff IJ (1979) Nephrotoxicity of cis-dichloroplatinum(II). Cancer Treat Rep 63: 1523
Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozeneweig M, Young RC, Muggia FM (1979) Toxic effects ofcis-dichlorodiammine platinum (II) in man. Cancer Treat Rep 63: 1527
Fillastre JP, Raguenez-Viotte G (1989) Cisplatin nephrotoxicity. Toxicol Lett 46: 163
Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938
Groth S, Nielsen H, Sorensen JB (1986) Acute and long-term nephrotoxicity of cisplatinum in man. Cancer Chemother Pharmacol 17: 191–196
Schwabe R, Herrmann R, Mathew M, Graf KJ, Sander T, Cordes M, Nagel R, Weissbach L, Huhn D (1992) Langfristige Toxizität der Polychemotherapie bei kurativ behandeltem Hodenkarzinom. Dtsch Med Wochenschr 117: 121–126
Roth BJ, Greist A, Kubilis PS, Williams LD, Einhorn LH (1988) Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 6: 1239–1247
Greene MH (1992) Is cisplatin a human carcinogen? J Natl Cancer Inst 84: 306–312
International Ageney for Research on Cancer (1987) Overall evaluations of carcinogenity: an updating of IARC Monograph volumes 1 to 42. IARC Monogr [Suppl 7]: 170–171
Ensslin A, Pethran A, Schierl R, Fruhmann G (1994) Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Environ Health 65: 339
Messerschmidt J, Alt F, Tölg G, Angerer J, Schaller KH (1992) Adsorptive voltammetric procedure for the determination of platinum baseline levels in human body fluids. Fresenius Z Anal Chem 343: 391
Vaughan GT, Florence TM (1992) Platinum in the human diet, blood, hair and excreta. Sci Tot Environ 111: 47
Schierl R, Ensslin AS, Fruhmann G (1994) Führt der Straßenverkehr zu erhöhten Platinkonzentrationen im Urin von beruflich Exponierten? Verh Dtsch Ges Arbeitsmed 33: 291–294
Preusser P, Achterrath W, Niederle N, Seeber S (1985) Cisplatin. Arzneimitteltherapie 3: 50
Harland S, Newell D, Siddik Z, Chadwick R, Chadwick R, Calvert H, Harrap KR (1984) Pharmacokinetics ofcis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44: 1693
Gormeley P, Bull J, LeRoy A, Cysyk R (1979) Kinetics ofcis-dichlorodiammineplatinum. Clin Pharmacol Ther 25: 351
Ehninger G, Haag C, Wilms K (1984) Die Pharmakokinetik voncis-Diaminodichloroplatin. Tumor Diagn Ther 5: 147
Shani J, Bertram J, Russell C, Dahalan R, Chen CP, Parti R, ahmadi J, Kempf RA, Kawada TK, Muggia FM, Wolf W (1989) Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans. Cancer Res 49: 1877
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schierl, R., Rohrer, B. & Hohnloser, J. Long-term platinum excretion in patients treated with cisplatin. Cancer Chemother. Pharmacol. 36, 75–78 (1995). https://doi.org/10.1007/BF00685736
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685736